News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Tishcon Corporation Receives Orphan Drug Designations For Coenzyme Q10 In The Treatment Of Pediatric Congestive Heart Failure And Huntington's Disease


10/19/2005 5:10:57 PM

WESTBURY, N.Y., April 19 /PRNewswire/ -- Tishcon Corp. announced that the U.S. FDA has granted the firm Orphan Drug Designations for UBIQUINOL (Coenzyme Q10) in the treatment of

1- Pediatric Congestive Heart Failure, and 2- Huntington's Disease

Tishcon Corp. was also granted an Orphan Drug Designation for Coenzyme Q10 (Ubi-Q-Gel(R)) in the treatment of Mitochondrial Cytopathies, in 1999.

Tishcon Corp.

CONTACT: Raj Chopra, Chairman, CEO of Tishcon Corp., +1-516-333 3050,Raj@Tishcon.com


Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES